Insoluble α-synuclein in alzheimer’s disease without lewy body formation
- 61 Downloads
Insoluble α-synuclein plays a central role in Lewy body diseases, with considerable controversy as to whether it plays a similar role in Alzheimer’s disease (AD). We assessed the tissue location and solubility of cortical α-synuclein in AD (without Lewy body formation) compared with controls, using sequential extraction procedures and Western immunoblotting to quantify different α-synuclein species in their different solubility states. Controls had no insoluble cortical α-synuclein and a ratio of soluble :lipid-associated α-synuclein of 1.2 ± 0.1. Total α-synuclein protein was significantly increased in AD and concentrated within the lipidassociated fraction (soluble :lipid ratio 0.9 ± 0.05, soluble:insoluble 1.5 ± 0.1, lipid:insoluble 1.7 ± 0.1) which proved difficult to localize in paraffinembedded tissue. Tissues prepared without lipid extraction revealed α-synuclein-immunoreactivity in the amorphous components of mature cored AD plaques. This lipid-association of α-synuclein in mature AD plaques links this protein with other lipid changes thought to be important in disease pathogenesis.
KeywordsAlzheimer’s disease Senile plaques α-Synuclein Protein solubility
Unable to display preview. Download preview PDF.
- Arima K, T Mizutani, MA Alim, H Tonozuka-Uehara, Y Izumiyama, S Hirai and K Ueda (2000) NACP/α-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies.Acta Neuropathol. 100, 115–121.PubMedCrossRefGoogle Scholar
- Bayer TA, P Jakala, T Hartmann, L Havas, C McLean, JG Culvenor, QX Li, CL Masters, P Falkai and K Beyreuther (1999) α-Synuclein accumulates in Lewy bodies in Parkinson’s disease and dementia with Lewy bodies but not in Alzheimer’s disease β-amyloid plaque cores.Neurosci. Lett. 266, 213–216.PubMedCrossRefGoogle Scholar
- Lippa CF, H Fujiwara, DMA Mann, B Gaisson, M Baba, ML Schmidt, LE Nee, B O’Connell, DA Pollen, P St George-Hyslop, B Ghetti, D Nochlin, TD Bird, NJ Cairns, VMY Lee, T Iwatsubo and JQ Trojanowski (1998) Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes.Am. J. Pathol. 153, 1365–1370.PubMedGoogle Scholar
- Masliah E, E Rockenstein, I Veinbergs, Y Sagara, M Mallory, M Hashimoto and L Mucke (2001) β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic model linking Alzheimer’s disease and Parkinson’s disease.Proc. Natl. Acad. Sci. USA 98, 12245–12250.PubMedCrossRefGoogle Scholar
- Michikawa M, J-S Gong, Q-W Fan, N Sawamura and K Yanagisawa (2001) A novel action of Alzheimer’s amyloid β-protein (Aβ): oligomeric Aβ promotes lipid release.J. Neurosci. 15, 7226–7235.Google Scholar
- Mukaetova-Ladinska EB, F Garcia-Siera, J Hurt, HJ Gertz, J Xuereb, R Hills, C Brayne, FA Huppert, ES Paykel, M McGee, R Jakes, WG Honer, CR Harrington and CM Wischik (2000a) Staging of cytoskeletal and β-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer’s disease.Am. J. Pathol. 157, 623–636.PubMedGoogle Scholar
- Paik S, J-H Lee, D-H Kim, C-S Chang and Y-S Kim (1998) Selfoligomerization of NACP, the precursor protein of the non-amyloid β/A4 protein (Aβ) component of Alzheimer’s disease amyloid, observed in the presence of a C-terminal Aβ fragment (residues 25-35).FEBS Lett. 421, 73–76.PubMedCrossRefGoogle Scholar
- Refolo LM, MA Pappolla, J LaFrancois, B Malester, SD Schmidt, T Thomas-Bryant, GS Tint, R Wang, M Mercken, SS Petanceska and KE Duff (2001) A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer’s disease.Neurobiol. Dis. 8, 890–899.PubMedCrossRefGoogle Scholar
- Rekas A, CG Adda, JA Aquilina, KJ Barnham, M Sunde, D Galatis, NA Williamson, CL Masters, RF Anders, CV Robinson, R appai and JA Carver (2004) Interaction of the molecular chaperone αB-crystallin with α-synuclein: effects on amyloid fibril formation and chaperone activity.J. Mol. Biol. 340, 1167–1183.PubMedCrossRefGoogle Scholar